mRNA-1010

DB22484ApprovedVaccines

mRNA-1010 is an mRNA-based seasonal influenza vaccine indicated for active immunization against influenza A and B in adults 50 years and older, using lipid nanoparticle–delivered mRNA encoding influenza hemagglutinin to elicit protective immunity. Each dose contains three mRNAs encapsulated in lipid nanoparticles, each encoding the hemagglutinin (HA) glycoprotein of one influenza strain recommended for the season; after intramuscular injection, host cells translate the mRNA into HA proteins that...

Mechanism: Pharmacologically active on Hemagglutinin
Curator reviewed
Primary indication: mFLUSIVA is a vaccine indicated for active immunization for the prevention of influenza disease caused by influenza virus subtypes A and type B represented in the vaccine. mFLUSIVA is approved for use in persons 50...Curator reviewed · 1 structured indication
Code names: mRNA-1010

Resolves to

Targets

P03437HA

What you can answer from here — as of September 02, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

290Drug interactionsStructured to mechanism, not free text

7Clinical trialsPhase, status and sponsor resolved per trial

1Structured indicationCondition, population, route and combination as fields, not prose

1ContraindicationEach with its own population and attribute set

6+ReferencesStructured and connected to the statements they support

Which drugs share a target with mRNA-1010, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account